Logo

KPTI

Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc. • NASDAQ
$5.62 ▲ 1.26% (+0.07)
Market Cap $47.98 M
52w High $12.90
52w Low $3.51
Dividend Yield 0%
P/E -0.38
Volume 34.66K
Outstanding Shares 8.54M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $44.044M ▲ $57.151M ▼ $-33.127M ▲ -75.213% ▲ $-3.82 ▲ $-22.56M ▲
Q2-2025 $37.929M ▲ $61.265M ▼ $-37.252M ▼ -98.215% ▼ $-4.32 ▼ $-25.906M ▼
Q1-2025 $30.015M ▼ $61.97M ▲ $-23.462M ▲ -78.168% ▲ $-2.77 ▲ $-12.354M ▲
Q4-2024 $30.542M ▼ $60.492M ▼ $-30.78M ▲ -100.779% ▼ $-3.67 ▲ $-19.604M ▲
Q3-2024 $38.783M $63.766M $-32.072M -82.696% $-3.85 $-20.576M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $45.877M ▼ $96.232M ▼ $365.49M ▲ $-269.258M ▼
Q2-2025 $51.697M ▼ $104.879M ▼ $343.805M ▲ $-238.926M ▼
Q1-2025 $69.941M ▼ $127.711M ▼ $333.595M ▼ $-205.884M ▼
Q4-2024 $108.712M ▼ $164.418M ▼ $350.435M ▲ $-186.017M ▼
Q3-2024 $133.526M $189.476M $349.123M $-159.647M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-33.127M ▲ $0 ▲ $0 ▼ $0 ▼ $-39.075M ▼ $0 ▲
Q2-2025 $-37.252M ▼ $-18.697M ▲ $18.285M ▲ $356K ▲ $-48K ▲ $-18.697M ▲
Q1-2025 $-23.462M ▲ $-38.984M ▼ $15.288M ▲ $0 ▼ $-23.691M ▼ $-38.984M ▼
Q4-2024 $-30.78M ▲ $-25.81M ▼ $14.797M ▲ $680K ▲ $-10.353M ▲ $-25.757M ▼
Q3-2024 $-32.072M $-19.453M $7.474M $0 $-11.943M $-19.453M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Health Care Other
Health Care Other
 $0 ▲$0 ▲$0 ▲$0 ▲
License and Service
License and Service
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
Other Royalty
Other Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has been small and fairly flat for several years, while operating costs have stayed much higher than sales. The company consistently reports operating and net losses, though the size of those losses has recently narrowed somewhat. This pattern is typical of a commercial‑stage biotech that has one main product and is still investing heavily in R&D and commercialization. Profitability is not yet in sight, and the very negative earnings per share and recent reverse stock split highlight how much financial pressure the business model is under at current scale.

Balance Sheet

Balance Sheet The balance sheet shows a lean asset base, limited cash compared with spending needs, and a meaningful amount of debt. Shareholders’ equity has moved into negative territory, which means obligations exceed recorded assets. That does not automatically signal distress, but it does indicate a thin financial cushion and heightened dependence on lenders and capital markets. Overall, financial flexibility looks constrained, and the company’s ability to support long trials and commercialization will likely hinge on ongoing access to outside funding or partnerships.

Cash Flow

Cash Flow The company has been burning cash from its operations every year, with free cash flow negative and closely matching operating cash outflows. Capital spending is minimal, so nearly all cash use is driven by operating losses, R&D, and commercialization costs. This is a classic “cash‑consuming” profile: the business is not yet self‑funding and will likely need periodic infusions of cash to continue executing its clinical and commercial plans unless revenue meaningfully scales up.

Competitive Edge

Competitive Edge Scientifically, Karyopharm occupies a differentiated niche with its first‑in‑class XPO1 inhibitor and SINE platform, and it already has an approved oncology drug on the market. Intellectual property protection, specialized know‑how in nuclear transport, and an existing oncology sales footprint provide a real, if narrow, moat. However, it competes in a fiercely contested cancer space against much larger, better‑capitalized firms and many alternative therapies. Dependence on a single main product and late‑line indications also exposes the company to competitive and reimbursement pressures if rival treatments show better efficacy, safety, or ease of use.

Innovation and R&D

Innovation and R&D Innovation is the core strength of the story. The company is pushing a novel biological mechanism, extending its lead drug into new cancers, and developing second‑generation and entirely new compounds that could improve tolerability and broaden use. Late‑stage trials in blood cancers and solid tumors, as well as additional pipeline assets, create multiple scientific and commercial “shots on goal.” At the same time, each trial brings clinical, regulatory, and financial risk: failures or delays could quickly strain resources, while successes could require significant additional investment or partners to fully realize their potential.

Summary

Karyopharm combines high scientific ambition with a financially stretched small‑cap biotech profile. On the positive side, it has a differentiated technology platform, an approved oncology drug, and a pipeline with several meaningful catalysts ahead. On the risk side, the company remains structurally unprofitable, relies on ongoing cash burn, carries notable debt, and has negative equity, leaving limited balance‑sheet buffer. Future outcomes will depend heavily on clinical trial results, the ability to expand use of its existing drug, competitive dynamics in oncology, and continued access to funding or strategic collaborations. This is a high‑uncertainty situation where scientific progress and financial strength need to be watched together over time.

NEWS

November 3, 2025 · 4:05 PM UTC

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 3, 2025 · 7:00 AM UTC

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Read more

October 27, 2025 · 7:00 AM UTC

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Read more

October 8, 2025 · 7:00 AM UTC

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Read more

October 1, 2025 · 4:05 PM UTC

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read more